We are a start-up company from the University of Oxford looking to become a leader in imaging biomarkers.
Alastair Buchan, co-founded Brainomix and is the Dean of Medicine and Professor of Stroke Medicine at the University of Oxford. He invented The Alberta Stroke Program Early CT Score (ASPECTS) clinical scoring methodology for detecting and assessing signs of stroke damage on computed tomography (CT) scans.
Our offices are in Summertown in Oxford and we’ve got a multidisciplinary team of experts working on commercialising medical imaging technologies.
Addressing neurological and cerebrovascular disorders
We are here to revolutionise and improve the treatment of patients with neurological and cerebrovascular disorders.
Strokes – a worldwide problem
Worldwide annually, 13,000,000 patients suffer a stroke. Mechanical clot removal (endovascular treatment) is expected to increase from 1% to 10% of patients, as recent studies show it improves patient outcome. It costs up to £23,000 per patient, making patient selection crucial for its adoption.
Medical imaging software
We have already developed and validated the medical imaging software, e-ASPECTS for plain CT images, with funding support from Innovate UK. Next we will build on this know-how to design, develop and validate perfusion-ASPECTS. Perfusion-ASPECTS will automate the clinically validated ASPECTS method on perfusion CTs to quantify tissue at risk and identify patients who can benefit from endovascular treatment.
Going international to help more people
We are currently entering international markets, and aim to increase revenues and employment both in the UK and worldwide. We are looking to be the international leader in imaging biomarkers for cerebrovascular disorders. We hope to become market leaders in order to assist as many physicians, and in turn, patients, as possible.
Getting in touch with Brainomix
Follow us on Twitter: @Brainomix
Find us on LinkedIn: https://www.linkedin.com/company/brainomix
You can follow Innovate UK on: